when was subutex discontinued

Subutex Tablets: Uses, Safety, and Patient Guidance

Subutex is a prescription medication historically utilized within medically supervised opioid dependency treatment programs. Designed to assist individuals navigating the challenges of opioid use disorder, Subutex functions as a partial opioid agonist-antagonist, specifically containing the active ingredient buprenorphine hydrochloride. By binding selectively to the mu-opioid receptors in the brain, it helps mitigate withdrawal symptoms and reduces cravings associated with opioid dependency without producing the same intense euphoria or sedation characteristic of full agonists.

Understanding how Subutex works requires examining its pharmacological profile. As a partial agonist, it creates a ceiling effect, meaning that beyond a certain dosage, increases in the dose do not result in further increases in agonist effects. This unique mechanism significantly lowers the risk of respiratory depression and overdose compared to full opioid agonists. When administered sublingually—dissolving completely under the tongue—the medication is absorbed directly through the mucosal lining into the bloodstream, bypassing first-pass hepatic metabolism for efficient bioavailability.

For individuals undergoing medically managed detoxification or maintenance therapy, integrating Subutex into a comprehensive treatment plan offers several distinct benefits. It stabilizes brain chemistry, restores physiological equilibrium, and allows patients to engage more fully in counseling, behavioral therapy, and daily responsibilities. Safety and efficacy, however, depend heavily on strict medical supervision, proper dosing schedules, and compliance with healthcare provider instructions. Common safety guidelines dictate regular monitoring for potential side effects such as headache, nausea, dizziness, insomnia, or localized oral discomfort.

Longevity and proper storage are critical components of maintaining pharmaceutical integrity. Subutex tablets should be stored in a controlled environment protected from excessive moisture, heat, and direct light to ensure the active compound remains potent throughout its designated shelf life. For those seeking reliable access to pharmaceutical care and related medical resources, visiting our pharmacy homepage offers secure navigation to a wide array of accredited healthcare supplies, educational materials, and professional customer support dedicated to patient wellness and satisfaction.

Product Details Table

Specification Category Details
Brand / Manufacturer Indivior / Reckitt Benckiser Pharmaceuticals
Composition / Ingredients Buprenorphine Hydrochloride
Concentration / Volume Available in 2 mg and 8 mg sublingual tablets
Duration of Effects 24 to 48 hours (depending on individual metabolic response)
Indications / Usage Areas Management and treatment of opioid use disorder
Injection Depth / Method Sublingual administration (dissolved under the tongue)
Shelf Life 24 to 36 months from the date of manufacture
Storage Conditions Store at controlled room temperature between 20°C and 25°C (68°F to 77°F)
Package Contents Blister packs containing 7, 14, or 30 sublingual tablets
Country of Origin United States / United Kingdom (Manufacturing facilities vary by batch)
Licensing / Certification FDA-approved, GMP certified, and EMA compliant
Safety Notes / Side Effects May cause headache, nausea, insomnia, or dizziness. Risk of dependence; use strictly under medical supervision.

Showing the single result

Shopping Cart